Literature DB >> 28074047

Arabilin overcomes resistance to AR-targeted therapy.

Takahiro Fujimaki1, Shun Saito1, Masaya Imoto1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28074047     DOI： 10.1038/ja.2016.162

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  14 in total

1.  The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.

Authors:  Mary Szatkowski Ozers; Bryan D Marks; Krishne Gowda; Kevin R Kupcho; Kerry M Ervin; Therese De Rosier; Naveeda Qadir; Hildegard C Eliason; Steven M Riddle; Mohammed Saleh Shekhani
Journal:  Biochemistry       Date:  2007-01-23       Impact factor: 3.162

Review 2.  Chemical biology of compounds obtained from screening using disease models.

Authors:  Estu Tashiro; Masaya Imoto
Journal:  Arch Pharm Res       Date:  2015-07-17       Impact factor: 4.946

3.  Total synthesis of the potent androgen receptor antagonist (-)-arabilin: a strategic, biomimetic [1,7]-hydrogen shift.

Authors:  Hee Nam Lim; Kathlyn A Parker
Journal:  J Am Chem Soc       Date:  2011-11-29       Impact factor: 15.419

Review 4.  Androgen receptor in prostate cancer.

Authors:  Cynthia A Heinlein; Chawnshang Chang
Journal:  Endocr Rev       Date:  2004-04       Impact factor: 19.871

5.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

6.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

7.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Authors:  Manav Korpal; Joshua M Korn; Xueliang Gao; Daniel P Rakiec; David A Ruddy; Shivang Doshi; Jing Yuan; Steve G Kovats; Sunkyu Kim; Vesselina G Cooke; John E Monahan; Frank Stegmeier; Thomas M Roberts; William R Sellers; Wenlai Zhou; Ping Zhu
Journal:  Cancer Discov       Date:  2013-07-10       Impact factor: 39.397

8.  Overcoming mutation-based resistance to antiandrogens with rational drug design.

Authors:  Minna D Balbas; Michael J Evans; David J Hosfield; John Wongvipat; Vivek K Arora; Philip A Watson; Yu Chen; Geoffrey L Greene; Yang Shen; Charles L Sawyers
Journal:  Elife       Date:  2013-04-09       Impact factor: 8.140

9.  Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.

Authors:  Nada Lallous; Stanislav V Volik; Shannon Awrey; Eric Leblanc; Ronnie Tse; Josef Murillo; Kriti Singh; Arun A Azad; Alexander W Wyatt; Stephane LeBihan; Kim N Chi; Martin E Gleave; Paul S Rennie; Colin C Collins; Artem Cherkasov
Journal:  Genome Biol       Date:  2016-01-26       Impact factor: 13.583

10.  Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.

Authors:  Emmanuel S Antonarakis; Chandtip Chandhasin; Erica Osbourne; Jun Luo; Marianne D Sadar; Frank Perabo
Journal:  Oncologist       Date:  2016-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.